|
|
 | | | |
- close
- close
- close
- close
CNNMoney.com
Feb 24
Comment
One study puts the potential overall cost of painkiller abuse at more than $70 billion a year. Pill addicts who shop around for doctors to score prescriptions cost insurers $10,000 to $15,000 apiece. The toll in lost productivity: $42 billion. The...
BusinessWeek
Feb 24
Comment
Vivus Inc. gained the most in 12 years after the company’s pill Qnexa won the backing of a regulatory panel, moving the drug a step closer to gaining U.S. approval as the first new obesity treatment in 13 years.
BusinessWeek
Feb 23
Comment
Vivus Inc. gained the most in 12 years after the company’s pill Qnexa won the backing of a regulatory panel, moving the drug a step closer to gaining U.S. approval as the first new obesity treatment in 13 years.
Wall Street Sector Selector
Feb 23
Comment
I've maintained for years that "debt destruction is the medicine we need to take," as opposed to "synthetic drugs that have masked the symptoms” after years of societal largess.
FiercePharma
Feb 23
Comment
An FDA advisory panel gave unexpectedly strong support to Qnexa, a diet pill from Vivus ($VVUS) that would be the first new weight loss pill to hit the U.S. market in 13 years. Analysts now consider FDA approval as "pretty much a done deal," as...
BusinessWeek
Feb 23
Comment
If the company's pill Qnexa is approved, it could generate $500 million in sales over the next few years
Clusterstock
Feb 23
Comment
SILVER SPRING, Md. (AP) — A previously rejected weight loss pill won an overwhelming endorsement from public health advisers Wednesday, raising hopes that the drug from Vivus Inc. could become the first new anti-obesity medication to reach the...
BusinessWeek
Feb 22
Comment
Vivus Inc.’s weight-loss pill Qnexa won the backing of a U.S. advisory panel as the company seeks to gain approval for the first new obesity drug in 13 years.
StreetInsider.com
Feb 21
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Dollar+Thrifty+%28DTG%29+Extends+Duration+of+Poison+Pill+Through+May+2013/7195479.html for the full story.
CNNMoney.com
Feb 20
Comment
Michael W. Klein is a professor at Tuft University's Fletcher School and a Non-Resident Senior Fellow in Economic Studies at The Brookings Institution. Klein recently served as chief economist for the Office of International Affairs at the U.S....
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS| This company has recently filed for protection under Chapter 11 of the U.S. Bankruptcy Code. |
References
| |||||||
